A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia
- 23 October 2012
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 13 (6) , 498-506
Abstract
Methotrexate (MTX) is an important component of therapy used to treat childhood acute lymphoblastic leukemia (ALL). Two single-nucleotide polymorphisms (SNPs) in the methylenetetrahydrofolate reductase (MTHFR) gene, C677T and A1298C, affect MTHFR activity. A large body of studies has investigated the potential role of MTHFR SNPs in MTX toxicity in pediatric ALL. However, the results are controversial. In this review and meta-analysis, we critically evaluate the relationship between the C677T and A1298C polymorphisms of MTHFR and MTX toxicity in pediatric ALL. The majority of published reports do not find associations between MTHFR polymorphisms and toxicity in pediatric ALL. When associations are reported, often the results are contradictory to each other. The meta-analysis confirms a lack of association. In conclusion, MTHFR, C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity in pediatric ALL.Keywords
This publication has 37 references indexed in Scilit:
- Germline genetic variation and treatment response on CCG‐1891Pediatric Blood & Cancer, 2011
- Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese populationLeukemia & Lymphoma, 2011
- Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemiaLeukemia & Lymphoma, 2010
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical EffectsJournal of Clinical Oncology, 2009
- C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisationEuropean Journal of Cancer, 2009
- Ancestry and pharmacogenetics of antileukemic drug toxicityBlood, 2007
- Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapyNature Reviews Cancer, 2006
- Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemiaEuropean Journal of Cancer, 2006
- Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemiaThe Pharmacogenomics Journal, 2003
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995